Gällande vårdprogram levercellscancer

Fastställt av Regionala cancercentrum i samverkan 2015-06-16

22. Referenser

    1. Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. Journal of clinical gastroenterology. 2013 Jul;47 Suppl:S2-6. PubMed PMID: 23632345. Pubmed Central PMCID: 3683119.
    2. Kaczynski J, Hansson G, Wallerstedt S. Incidence of primary liver cancer and aetiological aspects: a study of a defined population from a low-endemicity area. British journal of cancer. 1996 Jan;73(1):128-32. PubMed PMID: 8554975. Pubmed Central PMCID: 2074294.
    3. Edenvik P,  Davidsdottir L, Oksanen A, Isaksson B, Hultcrantz R, Stål P. Kliniskt spektrum och behandlingspanorama av hepatocellulär cancer i Stockholm 2005-2012. Svenska Gastrodagarna 2013.
    4. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. Journal of hepatology. 2006 Oct;45(4):529-38. PubMed PMID: 16879891.
    5. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. Journal of viral hepatitis. 2004 Mar;11(2):97-107. PubMed PMID: 14996343.
    6. Global Burden Of Hepatitis CWG. Global burden of disease (GBD) for hepatitis C. Journal of clinical pharmacology. 2004 Jan;44(1):20-9. PubMed PMID: 14681338.
    7. Raza SA, Clifford GM, Franceschi S. Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. British journal of cancer. 2007 Apr 10;96(7):1127-34. PubMed PMID: 17406349. Pubmed Central PMCID: 2360117.
    8. Hutchinson SJ, Bird SM, Goldberg DJ. Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland. Hepatology (Baltimore, Md). 2005 Sep;42(3):711-23. PubMed PMID: 16116637.
    9. Sweeting MJ, De Angelis D, Brant LJ, Harris HE, Mann AG, Ramsay ME. The burden of hepatitis C in England. Journal of viral hepatitis. 2007 Aug;14(8):570-6. PubMed PMID: 17650291.
    10. Strauss R, Torner A, Duberg AS, Hultcrantz R, Ekdahl K. Hepatocellular carcinoma and other primary liver cancers in hepatitis C patients in Sweden - a low endemic country. Journal of viral hepatitis. 2008 Jul;15(7):531-7. PubMed PMID: 18397224.
    11. Duberg AS, Pettersson H, Aleman S, Blaxhult A, Daviethsdottir L, Hultcrantz R, et al. The burden of hepatitis C in Sweden: a national study of inpatient care. Journal of viral hepatitis. 2011 Feb;18(2):106-18. PubMed PMID: 20158602.
    12. Davidsdottir L, Duberg AS, Torner A, Aleman S, Back E, Ekdahl K, et al. Hepatocellular carcinoma in individuals with HBV infection or HBV-HCV co-infection in a low endemic country. Scandinavian journal of gastroenterology. 2010 Aug;45(7-8):944-52. PubMed PMID: 20384529.
    13. Duberg AS, Torner A, Davidsdottir L, Aleman S, Blaxhult A, Svensson A, et al. Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community-based register study. Journal of viral hepatitis. 2008 Jul;15(7):538-50. PubMed PMID: 18397223.
    14. Bjornsson E, Angulo P. Non-alcoholic fatty liver disease. Scandinavian journal of gastroenterology. 2007 Sep;42(9):1023-30. PubMed PMID: 17710666.
    15. Elmberg M, Hultcrantz R, Ekbom A, Brandt L, Olsson S, Olsson R, et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology. 2003 Dec;125(6):1733-41. PubMed PMID: 14724826.
    16. Werner M, Prytz H, Ohlsson B, Almer S, Bjornsson E, Bergquist A, et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scandinavian journal of gastroenterology. 2008;43(10):1232-40. PubMed PMID: 18609163.
    17. Werner M, Almer S, Prytz H, Lindgren S, Wallerstedt S, Bjornsson E, et al. Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients. Journal of hepatology. 2009 Feb;50(2):388-93. PubMed PMID: 19070390.
    18. Innala E, Andersson C. Screening for hepatocellular carcinoma in acute intermittent porphyria: a 15-year follow-up in northern Sweden. Journal of internal medicine. 2011 May;269(5):538-45. PubMed PMID: 21198994.
    19. Sardh E, Wahlin S, Bjornstedt M, Harper P, Andersson DE. High risk of primary liver cancer in a cohort of 179 patients with Acute Hepatic Porphyria. Journal of inherited metabolic disease. 2013 Nov;36(6):1063-71. PubMed PMID: 23344888.
    20. Cassiman D, Vannoote J, Roelandts R, Libbrecht L, Roskams T, Van den Oord J, et al. Porphyria cutanea tarda and liver disease. A retrospective analysis of 17 cases from a single centre and review of the literature. Acta gastro-enterologica Belgica. 2008 Apr-Jun;71(2):237-42. PubMed PMID: 18720935.
    21. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003 Dec 6;362(9399):1907-17. PubMed PMID: 14667750.
    22. Cabibbo G, Maida M, Genco C, Parisi P, Peralta M, Antonucci M, et al. Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study. World journal of hepatology. 2012 Sep 27;4(9):256-61. PubMed PMID: 23060970. Pubmed Central PMCID: 3468702.
    23. Kaczynski J, Hansson G, Wallerstedt S. Diabetes: one of few remarkable differences in clinicopathologic features between cirrhotic and noncirrhotic Swedes with hepatocellular carcinoma. Dig Dis Sci. 2006 Apr;51(4):796-802. PubMed PMID: 16615006.
    24. Ebara M, Ohto M, Shinagawa T, Sugiura N, Kimura K, Matsutani S, et al. Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients. Gastroenterology. 1986 Feb;90(2):289-98. PubMed PMID: 2416627.
    25. Okazaki N, Yoshino M, Yoshida T, Suzuki M, Moriyama N, Takayasu K, et al. Evaluation of the prognosis for small hepatocellular carcinoma based on tumor volume doubling time. A preliminary report. Cancer. 1989 Jun 1;63(11):2207-10. PubMed PMID: 2541886.
    26. Kubota K, Ina H, Okada Y, Irie T. Growth rate of primary single hepatocellular carcinoma: determining optimal screening interval with contrast enhanced computed tomography. Dig Dis Sci. 2003 Mar;48(3):581-6. PubMed PMID: 12757173.
    27. Barbara L, Benzi G, Gaiani S, Fusconi F, Zironi G, Siringo S, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology (Baltimore, Md). 1992 Jul;16(1):132-7. PubMed PMID: 1352268.
    28. Taouli B, Goh JS, Lu Y, Qayyum A, Yeh BM, Merriman RB, et al. Growth rate of hepatocellular carcinoma: evaluation with serial computed tomography or magnetic resonance imaging. Journal of computer assisted tomography. 2005 Jul-Aug;29(4):425-9. PubMed PMID: 16012295.
    29. Aleman S, Rahbin N, Weiland O, Davidsdottir L, Hedenstierna M, Rose N, et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2013 Jul;57(2):230-6. PubMed PMID: 23616492.
    30. Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene. 2010 Apr 22;29(16):2309-24. PubMed PMID: 20228847. Pubmed Central PMCID: 3148694.
    31. Hassan MM, Spitz MR, Thomas MB, Curley SA, Patt YZ, Vauthey JN, et al. The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. Journal of hepatology. 2009 Feb;50(2):334-41. PubMed PMID: 19070394. Pubmed Central PMCID: 2658718.
    32. Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. Journal of viral hepatitis. 2009 Jul;16(7):453-63. PubMed PMID: 19302335.
    33. Volk ML, Lok AS. Is family history of liver cancer a risk factor for hepatocellular carcinoma? Journal of hepatology. 2009 Feb;50(2):247-8. PubMed PMID: 19070916.
    34. Bartosch B, Thimme R, Blum HE, Zoulim F. Hepatitis C virus-induced hepatocarcinogenesis. Journal of hepatology. 2009 Oct;51(4):810-20. PubMed PMID: 19545926.
    35. Batlle AM. Porphyrins, porphyrias, cancer and photodynamic therapy--a model for carcinogenesis. Journal of photochemistry and photobiology B, Biology. 1993 Sep;20(1):5-22. PubMed PMID: 8229469.
    36. Beasley RP, Hwang LY, Lee GC, Lan CC, Roan CH, Huang FY, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet. 1983 Nov 12;2(8359):1099-102. PubMed PMID: 6138642.
    37. Ip HM, Lelie PN, Wong VC, Kuhns MC, Reesink HW. Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA. Lancet. 1989 Feb 25;1(8635):406-10. PubMed PMID: 2563788.
    38. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. Journal of the National Cancer Institute. 2009 Oct 7;101(19):1348-55. PubMed PMID: 19759364.
    39. Poovorawan Y, Chongsrisawat V, Theamboonlers A, Leroux-Roels G, Kuriyakose S, Leyssen M, et al. Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region. Journal of viral hepatitis. 2011 May;18(5):369-75. PubMed PMID: 20384962. Pubmed Central PMCID: 3110864.
    40. Lim SG, Mohammed R, Yuen MF, Kao JH. Prevention of hepatocellular carcinoma in hepatitis B virus infection. Journal of gastroenterology and hepatology. 2009 Aug;24(8):1352-7. PubMed PMID: 19702903.
    41. Lindh M, Uhnoo I, Blackberg J, Duberg AS, Friman S, Fischler B, et al. Treatment of chronic hepatitis B infection: an update of Swedish recommendations. Scandinavian journal of infectious diseases. 2008;40(6-7):436-50. PubMed PMID: 18584530.
    42. Tran TT. Management of hepatitis B in pregnancy: weighing the options. Cleveland Clinic journal of medicine. 2009 May;76 Suppl 3:S25-9. PubMed PMID: 19465706.
    43. Lagging LM, Aneman C, Nenonen N, Brandberg A, Grip L, Norkrans G, et al. Nosocomial transmission of HCV in a cardiology ward during the window phase of infection: an epidemiological and molecular investigation. Scandinavian journal of infectious diseases. 2002;34(8):580-2. PubMed PMID: 12238573.
    44. Cardell K, Widell A, Fryden A, Akerlind B, Mansson AS, Franzen S, et al. Nosocomial hepatitis C in a thoracic surgery unit; retrospective findings generating a prospective study. The Journal of hospital infection. 2008 Apr;68(4):322-8. PubMed PMID: 18294726.
    45. Allander T, Gruber A, Naghavi M, Beyene A, Soderstrom T, Bjorkholm M, et al. Frequent patient-to-patient transmission of hepatitis C virus in a haematology ward. Lancet. 1995 Mar 11;345(8950):603-7. PubMed PMID: 7898176.
    46. Piorkowsky NY. Europe's hepatitis challenge: defusing the "viral time bomb". Journal of hepatology. 2009 Dec;51(6):1068-73. PubMed PMID: 19854528.
    47. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recommendations and reports : Morbidity and mortality weekly report Recommendations and reports / Centers for Disease Control. 2012 Aug 17;61(RR-4):1-32. PubMed PMID: 22895429.
    48. European Association For The Study Of The L. EASL Clinical Practice Guidelines: management of chronic hepatitis B. Journal of hepatology. 2009 Feb;50(2):227-42. PubMed PMID: 19054588.
    49. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004 Oct 7;351(15):1521-31. PubMed PMID: 15470215.
    50. Matsumoto A, Tanaka E, Rokuhara A, Kiyosawa K, Kumada H, Omata M, et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol Res. 2005 Jul;32(3):173-84. PubMed PMID: 16024289.
    51. Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antiviral therapy. 2007;12(8):1295-303. PubMed PMID: 18240869.
    52. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001 Sep 22;358(9286):958-65. PubMed PMID: 11583749.
    53. Asselah T, Marcellin P. Interferon free therapy with direct acting antivirals for HCV. Liver international : official journal of the International Association for the Study of the Liver. 2013 Feb;33 Suppl 1:93-104. PubMed PMID: 23286852.
    54. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology (Baltimore, Md). 2007 Mar;45(3):579-87. PubMed PMID: 17326216.
    55. Bruno S, Zuin M, Crosignani A, Rossi S, Zadra F, Roffi L, et al. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. The American journal of gastroenterology. 2009 May;104(5):1147-58. PubMed PMID: 19352340.
    56. Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. Journal of hepatology. 2010 May;52(5):652-7. PubMed PMID: 20346533.
    57. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2010 Mar;8(3):280-8, 8 e1. PubMed PMID: 19948249.
    58. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008 Dec 4;359(23):2429-41. PubMed PMID: 19052125. Pubmed Central PMCID: 2606037.
    59. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009 Jan;136(1):138-48. PubMed PMID: 18848939. Pubmed Central PMCID: 3749922.
    60. Franceschi S, Montella M, Polesel J, La Vecchia C, Crispo A, Dal Maso L, et al. Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2006 Apr;15(4):683-9. PubMed PMID: 16614109.
    61. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology (Baltimore, Md). 2002 Nov;36(5):1206-13. PubMed PMID: 12395331.
    62. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology (Baltimore, Md). 2010 Jun;51(6):1972-8. PubMed PMID: 20209604.
    63. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology (Baltimore, Md). 2010 May;51(5):1820-32. PubMed PMID: 20432259.
    64. Centis E, Marzocchi R, Di Domizio S, Ciaravella MF, Marchesini G. The effect of lifestyle changes in non-alcoholic fatty liver disease. Dig Dis. 2010;28(1):267-73. PubMed PMID: 20460922.
    65. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010 May 6;362(18):1675-85. PubMed PMID: 20427778. Pubmed Central PMCID: 2928471.
    66. Wojcik JP, Speechley MR, Kertesz AE, Chakrabarti S, Adams PC. Natural history of C282Y homozygotes for hemochromatosis. Canadian journal of gastroenterology = Journal canadien de gastroenterologie. 2002 May;16(5):297-302. PubMed PMID: 12045778.
    67. Salata H, Cortes JM, Enriquez de Salamanca R, Oliva H, Castro A, Kusak E, et al. Porphyria cutanea tarda and hepatocellular carcinoma. Frequency of occurrence and related factors. Journal of hepatology. 1985;1(5):477-87. PubMed PMID: 2997323.
    68. Lim HW, Mascaro JM. The porphyrias and hepatocellular carcinoma. Dermatologic clinics. 1995 Jan;13(1):135-42. PubMed PMID: 7712639.
    69. Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md). 2011 Mar;53(3):1020-2. PubMed PMID: 21374666. Pubmed Central PMCID: 3084991.
    70. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Alimentary pharmacology & therapeutics. 2009 Jul;30(1):37-47. PubMed PMID: 19392863.
    71. Lencioni R, Crocetti L, Della Pina MC, Cioni D. Guidelines for imaging focal lesions in liver cirrhosis. Expert review of gastroenterology & hepatology. 2008 Oct;2(5):697-703. PubMed PMID: 19072346.
    72. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Seminars in liver disease. 2010 Feb;30(1):52-60. PubMed PMID: 20175033.
    73. Sangiovanni A, Colombo M. Surveillance for hepatocellular carcinoma: a standard of care, not a clinical option. Hepatology (Baltimore, Md). 2011 Dec;54(6):1898-900. PubMed PMID: 21932397.
    74. Yu NC, Chaudhari V, Raman SS, Lassman C, Tong MJ, Busuttil RW, et al. CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2011 Feb;9(2):161-7. PubMed PMID: 20920597.
    75. Lee KF, Chong CN, Wong J, Cheung YS, Wong J, Lai P. Long-term results of laparoscopic hepatectomy versus open hepatectomy for hepatocellular carcinoma: a case-matched analysis. World journal of surgery. 2011 Oct;35(10):2268-74. PubMed PMID: 21842300. Epub 2011/08/16. eng.
    76. Golfieri R, Marini E, Bazzocchi A, Fusco F, Trevisani F, Sama C, et al. Small (<or=3 cm) hepatocellular carcinoma in cirrhosis: the role of double contrast agents in MR imaging vs. multidetector-row CT. La Radiologia medica. 2009 Dec;114(8):1239-66. PubMed PMID: 19697104.
    77. Kim SH, Choi BI, Lee JY, Kim SJ, So YH, Eun HW, et al. Diagnostic accuracy of multi-/single-detector row CT and contrast-enhanced MRI in the detection of hepatocellular carcinomas meeting the milan criteria before liver transplantation. Intervirology. 2008;51 Suppl 1:52-60. PubMed PMID: 18544949.
    78. Lee DH, Kim SH, Lee JM, Park HS, Lee JY, Yi NJ, et al. Diagnostic performance of multidetector row computed tomography, superparamagnetic iron oxide-enhanced magnetic resonance imaging, and dual-contrast magnetic resonance imaging in predicting the appropriateness of a transplant recipient based on milan criteria: correlation with histopathological findings. Investigative radiology. 2009 Jun;44(6):311-21. PubMed PMID: 19462486.
    79. Leoni S, Piscaglia F, Golfieri R, Camaggi V, Vidili G, Pini P, et al. The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. The American journal of gastroenterology. 2010 Mar;105(3):599-609. PubMed PMID: 19935786.
    80. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010 Feb;138(2):493-502. PubMed PMID: 19852963. Pubmed Central PMCID: 2819612.
    81. Singal AG, Conjeevaram HS, Volk ML, Fu S, Fontana RJ, Askari F, et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2012 May;21(5):793-9. PubMed PMID: 22374994.
    82. Gopal P, Yopp AC, Waljee AK, Chiang J, Nehra M, Kandunoori P, et al. Factors that affect accuracy of alpha-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2014 May;12(5):870-7. PubMed PMID: 24095974. Pubmed Central PMCID: 3975698.
    83. Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Seminars in oncology. 2012 Aug;39(4):410-33. PubMed PMID: 22846859.
    84. Masuzaki R, Karp SJ, Omata M. New serum markers of hepatocellular carcinoma. Seminars in oncology. 2012 Aug;39(4):434-9. PubMed PMID: 22846860.
    85. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004 Jul;130(7):417-22. PubMed PMID: 15042359.
    86. Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, Del Poggio P, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. Journal of hepatology. 2010 Aug;53(2):291-7. PubMed PMID: 20483497.
    87. Santagostino E, Colombo M, Rivi M, Rumi MG, Rocino A, Linari S, et al. A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. Blood. 2003 Jul 1;102(1):78-82. PubMed PMID: 12649165.
    88. Trevisani F, De Notariis S, Rapaccini G, Farinati F, Benvegnu L, Zoli M, et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). The American journal of gastroenterology. 2002 Mar;97(3):734-44. PubMed PMID: 11922571.
    89. Wang JH, Chang KC, Kee KM, Chen PF, Yen YH, Tseng PL, et al. Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community. The American journal of gastroenterology. 2013 Mar;108(3):416-24. PubMed PMID: 23318478.
    90. Trinchet JC. Surveillance for hepatocellular carcinoma in cirrhotic patients: from official recommendations to the real life. Journal of hepatology. 2011 Jun;54(6):1310-1. PubMed PMID: 21296113.
    91. European Association For The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of hepatology. 2012 Apr;56(4):908-43. PubMed PMID: 22424438.
    92. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004 Nov;127(5 Suppl 1):S35-50. PubMed PMID: 15508101.
    93. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. Journal of hepatology. 2008 Feb;48(2):335-52. PubMed PMID: 18096267.
    94. Kew MC, Hodkinson J, Paterson AC, Song E. Hepatitis-B virus infection in black children with hepatocellular carcinoma. Journal of medical virology. 1982;9(3):201-7. PubMed PMID: 6284871.
    95. European Association for Study of L, European Organisation for R, Treatment of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. European journal of cancer. 2012 Mar;48(5):599-641. PubMed PMID: 22424278.
    96. Iloeje UH, Yang HI, Chen CJ. Natural history of chronic hepatitis B: what exactly has REVEAL revealed? Liver international : official journal of the International Association for the Study of the Liver. 2012 Oct;32(9):1333-41. PubMed PMID: 22510145.
    97. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997 Feb;112(2):463-72. PubMed PMID: 9024300.
    98. Sun CA, Wu DM, Lin CC, Lu SN, You SL, Wang LY, et al. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. American journal of epidemiology. 2003 Apr 15;157(8):674-82. PubMed PMID: 12697571.
    99. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Annals of internal medicine. 2007 Nov 20;147(10):677-84. PubMed PMID: 18025443.
    100. Schoniger-Hekele M, Muller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A. Hepatocellular carcinoma in Austria: aetiological and clinical characteristics at presentation. European journal of gastroenterology & hepatology. 2000 Aug;12(8):941-8. PubMed PMID: 10958223.
    101. Jepsen P, Ott P, Andersen PK, Sorensen HT, Vilstrup H. Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish nationwide cohort study. Annals of internal medicine. 2012 Jun 19;156(12):841-7, W295. PubMed PMID: 22711076.
    102. Cavazza A, Caballeria L, Floreani A, Farinati F, Bruguera M, Caroli D, et al. Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. Hepatology (Baltimore, Md). 2009 Oct;50(4):1162-8. PubMed PMID: 19585656.
    103. Caballeria L, Pares A, Castells A, Gines A, Bru C, Rodes J. Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis. The American journal of gastroenterology. 2001 Apr;96(4):1160-3. PubMed PMID: 11316164.
    104. Silveira MG, Suzuki A, Lindor KD. Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis. Hepatology (Baltimore, Md). 2008 Oct;48(4):1149-56. PubMed PMID: 18785621.
    105. Fracanzani AL, Conte D, Fraquelli M, Taioli E, Mattioli M, Losco A, et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology (Baltimore, Md). 2001 Mar;33(3):647-51. PubMed PMID: 11230745.
    106. Yeoman AD, Al-Chalabi T, Karani JB, Quaglia A, Devlin J, Mieli-Vergani G, et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening. Hepatology (Baltimore, Md). 2008 Sep;48(3):863-70. PubMed PMID: 18752332.
    107. Teufel A, Weinmann A, Centner C, Piendl A, Lohse AW, Galle PR, et al. Hepatocellular carcinoma in patients with autoimmune hepatitis. World journal of gastroenterology : WJG. 2009 Feb 7;15(5):578-82. PubMed PMID: 19195059. Pubmed Central PMCID: 2653348
    108. Elzouki AN, Eriksson S. Risk of hepatobiliary disease in adults with severe alpha 1-antitrypsin deficiency (PiZZ): is chronic viral hepatitis B or C an additional risk factor for cirrhosis and hepatocellular carcinoma? European journal of gastroenterology & hepatology. 1996 Oct;8(10):989-94. PubMed PMID: 8930564
    109. Zhou H, Ortiz-Pallardo ME, Ko Y, Fischer HP. Is heterozygous alpha-1-antitrypsin deficiency type PIZ a risk factor for primary liver carcinoma? Cancer. 2000 Jun 15;88(12):2668-76. PubMed PMID: 10870048
    110. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2012 Dec;10(12):1342-59 e2. PubMed PMID: 23041539. Pubmed Central PMCID: 3501546
    111. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut. 2001 Feb;48(2):251-9. PubMed PMID: 11156649. Pubmed Central PMCID: 1728189
    112. Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Cramp M, et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health technology assessment. 2007 Sep;11(34):1-206. PubMed PMID: 17767898.
    113. Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. The American journal of medicine. 1996 Oct;101(4):422-34. PubMed PMID: 8873514.
    114. Kaczynski J, Hansson G, Wallerstedt S. Clinical features in hepatocellular carcinoma and the impact of autopsy on diagnosis. A study of 530 cases from a low-endemicity area. Hepatogastroenterology. 2005 Nov-Dec;52(66):1798-802. PubMed PMID: 16334780.
    115. Kaczynski J, Hansson G, Wallerstedt S. Metastases in cases with hepatocellular carcinoma in relation to clinicopathologic features of the tumor. An autopsy study from a low endemic area. Acta oncologica. 1995;34(1):43-8. PubMed PMID: 7865235.
    116. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. Journal of hepatology. 2001 Sep;35(3):421-30. PubMed PMID: 11592607.
    117. Bruix J, Sherman M, Practice Guidelines Committee AAftSoLD. Management of hepatocellular carcinoma. Hepatology (Baltimore, Md). 2005 Nov;42(5):1208-36. PubMed PMID: 16250051.
    118. Kudo M, Tochio H. Intranodular blood supply correlates well with biological malignancy grade determined by tumor growth rate in pathologically proven hepatocellular carcinoma. Oncology. 2008;75 Suppl 1:55-64. PubMed PMID: 19092273.
    119. Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso JR, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology (Baltimore, Md). 2008 Jan;47(1):97-104. PubMed PMID: 18069697.
    120. Bolondi L, Gaiani S, Celli N, Golfieri R, Grigioni WF, Leoni S, et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology (Baltimore, Md). 2005 Jul;42(1):27-34. PubMed PMID: 15954118.
    121. Gish RG, Lencioni R, Di Bisceglie AM, Raoul JL, Mazzaferro V. Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. Expert review of gastroenterology & hepatology. 2012 Apr;6(2):173-85. PubMed PMID: 22375523.
    122. Becker-Weidman DJ, Kalb B, Sharma P, Kitajima HD, Lurie CR, Chen Z, et al. Hepatocellular carcinoma lesion characterization: single-institution clinical performance review of multiphase gadolinium-enhanced MR imaging--comparison to prior same-center results after MR systems improvements. Radiology. 2011 Dec;261(3):824-33. PubMed PMID: 21969663.
    123. Addley HC, Griffin N, Shaw AS, Mannelli L, Parker RA, Aitken S, et al. Accuracy of hepatocellular carcinoma detection on multidetector CT in a transplant liver population with explant liver correlation. Clinical radiology. 2011 Apr;66(4):349-56. PubMed PMID: 21295772.
    124. Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, Conte D, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. The American journal of gastroenterology. 2006 Mar;101(3):513-23. PubMed PMID: 16542288.
    125. Choi JW, Lee JM, Kim SJ, Yoon JH, Baek JH, Han JK, et al. Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker. Radiology. 2013 Jun;267(3):776-86. PubMed PMID: 23401584.
    126. Bartolozzi C, Battaglia V, Bargellini I, Bozzi E, Campani D, Pollina LE, et al. Contrast-enhanced magnetic resonance imaging of 102 nodules in cirrhosis: correlation with histological findings on explanted livers. Abdominal imaging. 2013 Apr;38(2):290-6. PubMed PMID: 23053453.
    127. Golfieri R, Grazioli L, Orlando E, Dormi A, Lucidi V, Corcioni B, et al. Which is the best MRI marker of malignancy for atypical cirrhotic nodules: hypointensity in hepatobiliary phase alone or combined with other features? Classification after Gd-EOB-DTPA administration. Journal of magnetic resonance imaging : JMRI. 2012 Sep;36(3):648-57. PubMed PMID: 22592930.
    128. Sherman M. The radiological diagnosis of hepatocellular carcinoma. The American journal of gastroenterology. 2010 Mar;105(3):610-2. PubMed PMID: 20203642.
    129. Lim KS. Diffusion-weighted MRI of hepatocellular carcinoma in cirrhosis. Clinical radiology. 2014 Jan;69(1):1-10. PubMed PMID: 24034549.
    130. Wu LM, Xu JR, Lu Q, Hua J, Chen J, Hu J. A pooled analysis of diffusion-weighted imaging in the diagnosis of hepatocellular carcinoma in chronic liver diseases. Journal of gastroenterology and hepatology. 2013 Feb;28(2):227-34. PubMed PMID: 23190006.
    131. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014 May;63(5):844-55. PubMed PMID: 24531850.
    132. Schima W, Hammerstingl R, Catalano C, Marti-Bonmati L, Rummeny EJ, Montero FT, et al. Quadruple-phase MDCT of the liver in patients with suspected hepatocellular carcinoma: effect of contrast material flow rate. AJR American journal of roentgenology. 2006 Jun;186(6):1571-9. PubMed PMID: 16714645.
    133. Yanaga Y, Awai K, Nakaura T, Namimoto T, Oda S, Funama Y, et al. Optimal contrast dose for depiction of hypervascular hepatocellular carcinoma at dynamic CT using 64-MDCT. AJR American journal of roentgenology. 2008 Apr;190(4):1003-9. PubMed PMID: 18356448.
    134. Claudon M, Cosgrove D, Albrecht T, Bolondi L, Bosio M, Calliada F, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) - update 2008. Ultraschall in der Medizin. 2008 Feb;29(1):28-44. PubMed PMID: 18270887.
    135. Tarantino L, Francica G, Sordelli I, Esposito F, Giorgio A, Sorrentino P, et al. Diagnosis of benign and malignant portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma: color Doppler US, contrast-enhanced US, and fine-needle biopsy. Abdominal imaging. 2006 Sep-Oct;31(5):537-44. PubMed PMID: 16865315.
    136. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004 May;231(2):305-32. PubMed PMID: 15044750.
    137. Sun L, Guan YS, Pan WM, Chen GB, Luo ZM, Wei JH, et al. Highly metabolic thrombus of the portal vein: 18F fluorodeoxyglucose positron emission tomography/computer tomography demonstration and clinical significance in hepatocellular carcinoma. World journal of gastroenterology : WJG. 2008 Feb 28;14(8):1212-7. PubMed PMID: 18300346. Pubmed Central PMCID: 2690668.
    138. Brancatelli G, Federle MP, Grazioli L, Carr BI. Hepatocellular carcinoma in noncirrhotic liver: CT, clinical, and pathologic findings in 39 U.S. residents. Radiology. 2002 Jan;222(1):89-94. PubMed PMID: 11756710.
    139. Kim SH, Lim HK, Lee WJ, Cho JM, Jang HJ. Needle-tract implantation in hepatocellular carcinoma: frequency and CT findings after biopsy with a 19.5-gauge automated biopsy gun. Abdominal imaging. 2000 May-Jun;25(3):246-50. PubMed PMID: 10823443.
    140. Louha M, Nicolet J, Zylberberg H, Sabile A, Vons C, Vona G, et al. Liver resection and needle liver biopsy cause hematogenous dissemination of liver cells. Hepatology (Baltimore, Md). 1999 Mar;29(3):879-82. PubMed PMID: 10051492.
    141. Bru C, Maroto A, Bruix J, Faus R, Bianchi L, Calvet X, et al. Diagnostic accuracy of fine-needle aspiration biopsy in patients with hepatocellular carcinoma. Dig Dis Sci. 1989 Nov;34(11):1765-9. PubMed PMID: 2555123.
    142. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. The American journal of surgical pathology. 1995 Dec;19(12):1409-17. PubMed PMID: 7503362.
    143. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. Journal of hepatology. 1995 Jun;22(6):696-9. PubMed PMID: 7560864.
    144. Anatelli F, Chuang ST, Yang XJ, Wang HL. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy. American journal of clinical pathology. 2008 Aug;130(2):219-23. PubMed PMID: 18628090.
    145. Wee A. Diagnostic utility of immunohistochemistry in hepatocellular carcinoma, its variants and their mimics. Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry. 2006 Sep;14(3):266-72. PubMed PMID: 16932016.
    146. Edmonsson H, Steiner P. Primary carcinoma of the liver: a study of 100 cases among 48900 necropsies. Cancer. 1954:462-503.
    147. Pomfret EA, Washburn K, Wald C, Nalesnik MA, Douglas D, Russo M, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2010 Mar;16(3):262-78. PubMed PMID: 20209641.
    148. Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene. 2006 Jun 26;25(27):3818-22. PubMed PMID: 16799623.
    149. Plessier A, Codes L, Consigny Y, Sommacale D, Dondero F, Cortes A, et al. Underestimation of the influence of satellite nodules as a risk factor for post-transplantation recurrence in patients with small hepatocellular carcinoma. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2004 Feb;10(2 Suppl 1):S86-90. PubMed PMID: 14762846.
    150. Bioulac-Sage P, Laumonier H, Couchy G, Le Bail B, Sa Cunha A, Rullier A, et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology (Baltimore, Md). 2009 Aug;50(2):481-9. PubMed PMID: 19585623.
    151. Libbrecht L, Desmet V, Roskams T. Preneoplastic lesions in human hepatocarcinogenesis. Liver international : official journal of the International Association for the Study of the Liver. 2005 Feb;25(1):16-27. PubMed PMID: 15698394.
    152. Desmet VJ. East-West pathology agreement on precancerous liver lesions and early hepatocellular carcinoma. Hepatology (Baltimore, Md). 2009 Feb;49(2):355-7. PubMed PMID: 19127518.
    153. Kojiro M, Wanless IR, Alves V, Badve S, Balabaud C, Bedossa P, et al. Pathologic diagnosis of early hepatocellular carcinoma: a report of the International Consensus Group for Hepatocellular Neoplasia. HEPATOLOGY 2009; 49. DOI: 10.1002/hep.22709.
    154. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985 Aug 15;56(4):918-28. PubMed PMID: 2990661.
    155. Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB : the official journal of the International Hepato Pancreato Biliary Association. 2005;7(1):35-41. PubMed PMID: 18333159. Pubmed Central PMCID: 2023920.
    156. Farinati F, Rinaldi M, Gianni S, Naccarato R. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer. 2000 Dec 1;89(11):2266-73. PubMed PMID: 11147597.
    157. Ueno S, Tanabe G, Sako K, Hiwaki T, Hokotate H, Fukukura Y, et al. Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology (Baltimore, Md). 2001 Sep;34(3):529-34. PubMed PMID: 11526539.
    158. Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut. 2005 Mar;54(3):411-8. PubMed PMID: 15710992. Pubmed Central PMCID: 1774422.
    159. Nanashima A, Masuda J, Miuma S, Sumida Y, Nonaka T, Tanaka K, et al. Selection of treatment modality for hepatocellular carcinoma according to the modified Japan Integrated Staging score. World journal of gastroenterology : WJG. 2008 Jan 7;14(1):58-63. PubMed PMID: 18176962. Pubmed Central PMCID: 2673392.
    160. Leung TW, Tang AM, Zee B, Lau WY, Lai PB, Leung KL, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer. 2002 Mar 15;94(6):1760-9. PubMed PMID: 11920539.
    161. Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. Journal of hepatology. 1999 Jul;31(1):133-41. PubMed PMID: 10424293.
    162. Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology (Baltimore, Md). 2005 Apr;41(4):707-16. PubMed PMID: 15795889.
    163. Cillo U, Bassanello M, Vitale A, Grigoletto FA, Burra P, Fagiuoli S, et al. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? Journal of hepatology. 2004 Jan;40(1):124-31. PubMed PMID: 14672623.
    164. Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. Journal of hepatology. 2006 Apr;44(4):723-31. PubMed PMID: 16488051.
    165. Vitale A, Saracino E, Boccagni P, Brolese A, D'Amico F, Gringeri E, et al. Validation of the BCLC prognostic system in surgical hepatocellular cancer patients. Transplantation proceedings. 2009 May;41(4):1260-3. PubMed PMID: 19460533.
    166. Yeung YP, Lo CM, Liu CL, Wong BC, Fan ST, Wong J. Natural history of untreated nonsurgical hepatocellular carcinoma. The American journal of gastroenterology. 2005 Sep;100(9):1995-2004. PubMed PMID: 16128944.
    167. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology (Baltimore, Md). 1999 Dec;30(6):1434-40. PubMed PMID: 10573522.
    168. Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology (Baltimore, Md). 2000 Dec;32(6):1224-9. PubMed PMID: 11093728.
    169. Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg. 1999 Jun;229(6):790-9; discussion 9-800. PubMed PMID: 10363892. Pubmed Central PMCID: 1420825.
    170. Grazi GL, Ercolani G, Pierangeli F, Del Gaudio M, Cescon M, Cavallari A, et al. Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg. 2001 Jul;234(1):71-8. PubMed PMID: 11420485. Pubmed Central PMCID: 1421950.
    171. Bruix J, Castells A, Bosch J, Feu F, Fuster J, Garcia-Pagan JC, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology. 1996 Oct;111(4):1018-22. PubMed PMID: 8831597.
    172. Cunningham SC, Tsai S, Marques HP, Mira P, Cameron A, Barroso E, et al. Management of early hepatocellular carcinoma in patients with well-compensated cirrhosis. Annals of surgical oncology. 2009 Jul;16(7):1820-31. PubMed PMID: 19267161.
    173. Poon RT, Fan ST. Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2004 Feb;10(2 Suppl 1):S39-45. PubMed PMID: 14762838.
    174. Verslype C, Van Cutsem E, Dicato M, Arber N, Berlin JD, Cunningham D, et al. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann Oncol. 2009 Jun;20 Suppl 7:vii1-vii6. PubMed PMID: 19497945.
    175. Houben KW, McCall JL. Liver transplantation for hepatocellular carcinoma in patients without underlying liver disease: a systematic review. Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 1999 Mar;5(2):91-5. PubMed PMID: 10071346.
    176. Marin-Hargreaves G, Azoulay D, Bismuth H. Hepatocellular carcinoma: surgical indications and results. Critical reviews in oncology/hematology. 2003 Jul;47(1):13-27. PubMed PMID: 12853096.
    177. Fan ST, Poon RT, Yeung C, Lam CM, Lo CM, Yuen WK, et al. Outcome after partial hepatectomy for hepatocellular cancer within the Milan criteria. The British journal of surgery. 2011 Sep;98(9):1292-300. PubMed PMID: 21656513.
    178. Yeh CN, Chen MF, Lee WC, Jeng LB. Prognostic factors of hepatic resection for hepatocellular carcinoma with cirrhosis: univariate and multivariate analysis. J Surg Oncol. 2002 Dec;81(4):195-202. PubMed PMID: 12451624.
    179. Okada S, Shimada K, Yamamoto J, Takayama T, Kosuge T, Yamasaki S, et al. Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology. 1994 Jun;106(6):1618-24. PubMed PMID: 8194710.
    180. Poon RT, Fan ST. Assessment of hepatic reserve for indication of hepatic resection: how I do it. Journal of hepato-biliary-pancreatic surgery. 2005;12(1):31-7. PubMed PMID: 15754097.
    181. Chang WT, Kao WY, Chau GY, Su CW, Lei HJ, Wu JC, et al. Hepatic resection can provide long-term survival of patients with non-early-stage hepatocellular carcinoma: extending the indication for resection? Surgery. 2012 Nov;152(5):809-20. PubMed PMID: 22766361.
    182. Pelletier SJ, Fu S, Thyagarajan V, Romero-Marrero C, Batheja MJ, Punch JD, et al. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2009 Aug;15(8):859-68. PubMed PMID: 19642139.
    183. Dutkowski P, De Rougemont O, Mullhaupt B, Clavien PA. Current and future trends in liver transplantation in Europe. Gastroenterology. 2010 Mar;138(3):802-9 e1-4. PubMed PMID: 20096694.
    184. Xiaohong S, Huikai L, Feng W, Ti Z, Yunlong C, Qiang L. Clinical significance of lymph node metastasis in patients undergoing partial hepatectomy for hepatocellular carcinoma. World journal of surgery. 2010 May;34(5):1028-33. PubMed PMID: 20174806.
    185. Nanashima A, Sumida Y, Abo T, Takeshita H, Hidaka S, Sawai T, et al. Trisectionectomy for large hepatocellular carcinoma using the liver hanging maneuver. Eur J Surg Oncol. 2009 Mar;35(3):326-30. PubMed PMID: 18316172.
    186. Le Treut YP, Hardwigsen J, Ananian P, Saisse J, Gregoire E, Richa H, et al. Resection of hepatocellular carcinoma with tumor thrombus in the major vasculature. A European case-control series. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2006 Jun;10(6):855-62. PubMed PMID: 16769542.
    187. Vauthey JN, Lauwers GY, Esnaola NF, Do KA, Belghiti J, Mirza N, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol. 2002 Mar 15;20(6):1527-36. PubMed PMID: 11896101.
    188. Shi M, Zhang CQ, Zhang YQ, Liang XM, Li JQ. Micrometastases of solitary hepatocellular carcinoma and appropriate resection margin. World journal of surgery. 2004 Apr;28(4):376-81. PubMed PMID: 15022021.
    189. Strasberg SM. Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. Journal of hepato-biliary-pancreatic surgery. 2005;12(5):351-5. PubMed PMID: 16258801.
    190. Hasegawa K, Kokudo N, Imamura H, Matsuyama Y, Aoki T, Minagawa M, et al. Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg. 2005 Aug;242(2):252-9. PubMed PMID: 16041216. Pubmed Central PMCID: 1357731.
    191. Regimbeau JM, Kianmanesh R, Farges O, Dondero F, Sauvanet A, Belghiti J. Extent of liver resection influences the outcome in patients with cirrhosis and small hepatocellular carcinoma. Surgery. 2002 Mar;131(3):311-7. PubMed PMID: 11894036.
    192. Ariizumi S, Yamamoto M, Ohtsubo T, Katsuragawa H, Katagiri S, Takasaki K. Step classification is useful for the determination of indications for systematized hepatectomy in hepatocellular carcinoma. Journal of hepato-biliary-pancreatic surgery. 2005;12(5):371-7. PubMed PMID: 16258805.
    193. Tanaka K, Shimada H, Matsumoto C, Matsuo K, Nagano Y, Endo I, et al. Anatomic versus limited nonanatomic resection for solitary hepatocellular carcinoma. Surgery. 2008 May;143(5):607-15. PubMed PMID: 18436008.
    194. Shi M, Guo RP, Lin XJ, Zhang YQ, Chen MS, Zhang CQ, et al. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg. 2007 Jan;245(1):36-43. PubMed PMID: 17197963. Pubmed Central PMCID: 1867934.
    195. Eguchi S, Kanematsu T, Arii S, Okazaki M, Okita K, Omata M, et al. Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery. 2008 Apr;143(4):469-75. PubMed PMID: 18374043.
    196. Yamamoto M, Takasaki K, Ohtsubo T, Katsuragawa H, Fukuda C, Katagiri S. Effectiveness of systematized hepatectomy with Glisson's pedicle transection at the hepatic hilus for small nodular hepatocellular carcinoma: retrospective analysis. Surgery. 2001 Sep;130(3):443-8. PubMed PMID: 11562668.
    197. Dahiya D, Wu TJ, Lee CF, Chan KM, Lee WC, Chen MF. Minor versus major hepatic resection for small hepatocellular carcinoma (HCC) in cirrhotic patients: a 20-year experience. Surgery. 2010 May;147(5):676-85. PubMed PMID: 20004441.
    198. Gurusamy KS, Pamecha V, Sharma D, Davidson BR. Techniques for liver parenchymal transection in liver resection. Cochrane Database Syst Rev. 2009 (1):CD006880. PubMed PMID: 19160307.
    199. Kooby DA, Stockman J, Ben-Porat L, Gonen M, Jarnagin WR, Dematteo RP, et al. Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann Surg. 2003 Jun;237(6):860-9; discussion 9-70. PubMed PMID: 12796583. Pubmed Central PMCID: 1514683.
    200. Capussotti L, Muratore A, Ferrero A, Massucco P, Ribero D, Polastri R. Randomized clinical trial of liver resection with and without hepatic pedicle clamping. The British journal of surgery. 2006 Jun;93(6):685-9. PubMed PMID: 16703653.
    201. Pringle JH. V. Notes on the Arrest of Hepatic Hemorrhage Due to Trauma. Ann Surg. 1908 Oct;48(4):541-9. PubMed PMID: 17862242. Pubmed Central PMCID: 1406963.
    202. Gurusamy KS, Sheth H, Kumar Y, Sharma D, Davidson BR. Methods of vascular occlusion for elective liver resections. Cochrane Database Syst Rev. 2009 (1):CD007632. PubMed PMID: 19160340.
    203. Belghiti J, Noun R, Malafosse R, Jagot P, Sauvanet A, Pierangeli F, et al. Continuous versus intermittent portal triad clamping for liver resection: a controlled study. Ann Surg. 1999 Mar;229(3):369-75. PubMed PMID: 10077049. Pubmed Central PMCID: 1191702.
    204. Petrowsky H, McCormack L, Trujillo M, Selzner M, Jochum W, Clavien PA. A prospective, randomized, controlled trial comparing intermittent portal triad clamping versus ischemic preconditioning with continuous clamping for major liver resection. Ann Surg. 2006 Dec;244(6):921-8; discussion 8-30. PubMed PMID: 17122617. Pubmed Central PMCID: 1856627.
    205. Belghiti J, Noun R, Zante E, Ballet T, Sauvanet A. Portal triad clamping or hepatic vascular exclusion for major liver resection. A controlled study. Ann Surg. 1996 Aug;224(2):155-61. PubMed PMID: 8757378. Pubmed Central PMCID: 1235336.
    206. Gurusamy KS, Li J, Sharma D, Davidson BR. Cardiopulmonary interventions to decrease blood loss and blood transfusion requirements for liver resection. Cochrane Database Syst Rev. 2009 (4):CD007338. PubMed PMID: 19821405.
    207. Lai EC, Fan ST, Lo CM, Chu KM, Liu CL. Anterior approach for difficult major right hepatectomy. World journal of surgery. 1996 Mar-Apr;20(3):314-7; discussion 8. PubMed PMID: 8661837.
    208. Belghiti J, Guevara OA, Noun R, Saldinger PF, Kianmanesh R. Liver hanging maneuver: a safe approach to right hepatectomy without liver mobilization. J Am Coll Surg. 2001 Jul;193(1):109-11. PubMed PMID: 11442247.
    209. Liu CL, Fan ST, Cheung ST, Lo CM, Ng IO, Wong J. Anterior approach versus conventional approach right hepatic resection for large hepatocellular carcinoma: a prospective randomized controlled study. Ann Surg. 2006 Aug;244(2):194-203. PubMed PMID: 16858181. Pubmed Central PMCID: 1602174.
    210. Kim SH, Park SJ, Lee SA, Lee WJ, Park JW, Hong EK, et al. Various liver resections using hanging maneuver by three glisson's pedicles and three hepatic veins. Ann Surg. 2007 Feb;245(2):201-5. PubMed PMID: 17245172. Pubmed Central PMCID: 1876991.
    211. Xiong JJ, Altaf K, Javed MA, Huang W, Mukherjee R, Mai G, et al. Meta-analysis of laparoscopic vs open liver resection for hepatocellular carcinoma. World journal of gastroenterology : WJG. 2012 Dec 7;18(45):6657-68. PubMed PMID: 23236242. Pubmed Central PMCID: 3516221.
    212. Choi SB, Park JS, Kim JK, Hyung WJ, Kim KS, Yoon DS, et al. Early experiences of robotic-assisted laparoscopic liver resection. Yonsei medical journal. 2008 Aug 30;49(4):632-8. PubMed PMID: 18729307. Pubmed Central PMCID: 2615291.
    213. Yamashita Y, Hamatsu T, Rikimaru T, Tanaka S, Shirabe K, Shimada M, et al. Bile leakage after hepatic resection. Ann Surg. 2001 Jan;233(1):45-50. PubMed PMID: 11141224. Pubmed Central PMCID: 1421165.
    214. Gurusamy KS, Samraj K, Davidson BR. Routine abdominal drainage for uncomplicated liver resection. Cochrane Database Syst Rev. 2007 (3):CD006232. PubMed PMID: 17636837.
    215. Belghiti J, Regimbeau JM, Durand F, Kianmanesh AR, Dondero F, Terris B, et al. Resection of hepatocellular carcinoma: a European experience on 328 cases. Hepatogastroenterology. 2002 Jan-Feb;49(43):41-6. PubMed PMID: 11941981.
    216. Jaeck D, Bachellier P, Oussoultzoglou E, Weber JC, Wolf P. Surgical resection of hepatocellular carcinoma. Post-operative outcome and long-term results in Europe: an overview. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2004 Feb;10(2 Suppl 1):S58-63. PubMed PMID: 14762841.
    217. Kobayashi S, Gotohda N, Nakagohri T, Takahashi S, Konishi M, Kinoshita T. Risk factors of surgical site infection after hepatectomy for liver cancers. World journal of surgery. 2009 Feb;33(2):312-7. PubMed PMID: 19023613.
    218. Vivarelli M, Zanello M, Zanfi C, Cucchetti A, Ravaioli M, Del Gaudio M, et al. Prophylaxis for venous thromboembolism after resection of hepatocellular carcinoma on cirrhosis: is it necessary? World journal of gastroenterology : WJG. 2010 May 7;16(17):2146-50. PubMed PMID: 20440855. Pubmed Central PMCID: 2864840.
    219. Brunello F, Veltri A, Carucci P, Pagano E, Ciccone G, Moretto P, et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial. Scandinavian journal of gastroenterology. 2008;43(6):727-35. PubMed PMID: 18569991. Epub 2008/06/24. eng.
    220. Kuang M, Xie XY, Huang C, Wang Y, Lin MX, Xu ZF, et al. Long-term outcome of percutaneous ablation in very early-stage hepatocellular carcinoma. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2011 Dec;15(12):2165-71. PubMed PMID: 21972056. Epub 2011/10/06. eng.
    221. Li WH, Ma KW, Cheng M, Chui KH, Chan PT, Chu WH, et al. Radiofrequency ablation for hepatocellular carcinoma: a survival analysis of 117 patients. ANZ journal of surgery. 2010 Oct;80(10):714-21. PubMed PMID: 21040332. Epub 2010/11/03. eng.
    222. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut. 2005 Aug;54(8):1151-6. PubMed PMID: 16009687. Pubmed Central PMCID: PMC1774888. Epub 2005/07/13. eng.
    223. Liu JG, Wang YJ, Du Z. Radiofrequency ablation in the treatment of small hepatocellular carcinoma: a meta analysis. World journal of gastroenterology : WJG. 2010 Jul 21;16(27):3450-6. PubMed PMID: 20632451. Pubmed Central PMCID: PMC2904895. Epub 2010/07/16. eng.
    224. Tiong L, Maddern GJ. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. The British journal of surgery. 2011 Sep;98(9):1210-24. PubMed PMID: 21766289. Epub 2011/07/19. eng.
    225. Itoh S, Ikeda Y, Kawanaka H, Okuyama T, Kawasaki K, Eguchi D, et al. Efficacy of surgical microwave therapy in patients with unresectable hepatocellular carcinoma. Annals of surgical oncology. 2011 Dec;18(13):3650-6. PubMed PMID: 21674268. Epub 2011/06/16. eng.
    226. Liu FY, Yu XL, Liang P, Cheng ZG, Han ZY, Dong BW, et al. Microwave ablation assisted by a real-time virtual navigation system for hepatocellular carcinoma undetectable by conventional ultrasonography. European journal of radiology. 2012 Jul;81(7):1455-9. PubMed PMID: 21477961. Epub 2011/04/12. eng.
    227. Poggi G, Montagna B, P DIC, Riva G, Bernardo G, Mazzucco M, et al. Microwave ablation of hepatocellular carcinoma using a new percutaneous device: preliminary results. Anticancer research. 2013 Mar;33(3):1221-7. PubMed PMID: 23482806. Epub 2013/03/14. eng.
    228. Swan RZ, Sindram D, Martinie JB, Iannitti DA. Operative microwave ablation for hepatocellular carcinoma: complications, recurrence, and long-term outcomes. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2013 Apr;17(4):719-29. PubMed PMID: 23404173. Epub 2013/02/14. eng.
    229. Takami Y, Ryu T, Wada Y, Saitsu H. Evaluation of intraoperative microwave coagulo-necrotic therapy (MCN) for hepatocellular carcinoma: a single center experience of 719 consecutive cases. Journal of hepato-biliary-pancreatic sciences. 2013 Mar;20(3):332-41. PubMed PMID: 22710886. Pubmed Central PMCID: PMC3590403. Epub 2012/06/20. eng.
    230. Kwon JH, Bae SH, Kim JY, Choi BO, Jang HS, Jang JW, et al. Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC cancer. 2010;10:475. PubMed PMID: 20813065. Pubmed Central PMCID: PMC2940809. Epub 2010/09/04. eng.
    231. Takeda A, Sanuki N, Eriguchi T, Kobayashi T, Iwabutchi S, Matsunaga K, et al. Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma. Journal of gastroenterology and hepatology. 2013 Aug 8. PubMed PMID: 23927053. Epub 2013/08/10. Eng.
    232. Cassera MA, Potter KW, Ujiki MB, Swanstrom LL, Hansen PD. Computed tomography (CT)-guided versus laparoscopic radiofrequency ablation: a single-institution comparison of morbidity rates and hospital costs. Surgical endoscopy. 2011 Apr;25(4):1088-95. PubMed PMID: 20848143. Epub 2010/09/18. eng.
    233. Herbold T, Wahba R, Bangard C, Demir M, Drebber U, Stippel DL. The laparoscopic approach for radiofrequency ablation of hepatocellular carcinoma--indication, technique and results. Langenbeck's archives of surgery / Deutsche Gesellschaft fur Chirurgie. 2013 Jan;398(1):47-53. PubMed PMID: 23093087. Epub 2012/10/25. eng.
    234. Ni JY, Liu SS, Xu LF, Sun HL, Chen YT. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. World journal of gastroenterology : WJG. 2013 Jun 28;19(24):3872-82. PubMed PMID: 23840128. Pubmed Central PMCID: 3699038.
    235. Xu G, Qi FZ, Zhang JH, Cheng GF, Cai Y, Miao Y. Meta-analysis of surgical resection and radiofrequency ablation for early hepatocellular carcinoma. World journal of surgical oncology. 2012;10:163. PubMed PMID: 22897815. Pubmed Central PMCID: PMC3491005. Epub 2012/08/18. eng.
    236. Zhou Y, Zhao Y, Li B, Xu D, Yin Z, Xie F, et al. Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC gastroenterology. 2010;10:78. PubMed PMID: 20618937. Pubmed Central PMCID: PMC2914087. Epub 2010/07/14. eng.
    237. Perkins JD. Seeding risk following percutaneous approach to hepatocellular carcinoma. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2007 Nov;13(11):1603. PubMed PMID: 17969186. Epub 2007/10/31. eng.
    238. Koda M, Murawaki Y, Hirooka Y, Kitamoto M, Ono M, Sakaeda H, et al. Complications of radiofrequency ablation for hepatocellular carcinoma in a multicenter study: An analysis of 16 346 treated nodules in 13 283 patients. Hepatology research : the official journal of the Japan Society of Hepatology. 2012 May 10. PubMed PMID: 22583706. English.
    239. Liang P, Wang Y, Yu X, Dong B. Malignant liver tumors: treatment with percutaneous microwave ablation--complications among cohort of 1136 patients. Radiology. 2009 Jul;251(3):933-40. PubMed PMID: 19304921. English.
    240. Altekruse SF, McGlynn KA, Dickie LA, Kleiner DE. Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology (Baltimore, Md). 2012 Feb;55(2):476-82. PubMed PMID: 21953588. Epub 2011/09/29. eng.
    241. Francica G, Saviano A, De Sio I, De Matthaeis N, Brunello F, Cantamessa A, et al. Long-term effectiveness of radiofrequency ablation for solitary small hepatocellular carcinoma: a retrospective analysis of 363 patients. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2013 Apr;45(4):336-41. PubMed PMID: 23245589.
    242. Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. The American journal of gastroenterology. 2012 Apr;107(4):569-77; quiz 78. PubMed PMID: 22158026. Pubmed Central PMCID: PMC3321437. Epub 2011/12/14. eng.
    243. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009 Jan;10(1):35-43. PubMed PMID: 19058754. Epub 2008/12/09. eng.
    244. NLTR, Nordic Liver Transplant Registry